Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases (Digestive Diseases and Sciences, (2019), 64, 6, (1651-1659), 10.1007/s10620-019-05570-1)

Andres J. Yarur; Alexandra Bruss; Snehal Naik; Poonam Beniwal-Patel; Caroline Fox; Anjali Jain; Brandon Berens; Amir Patel; Ryan Ungaro; Bayda Bahur; Marla Dubinsky; Daniel J. Stein

doi:10.1007/s10620-019-05876-0

Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases (Digestive Diseases and Sciences, (2019), 64, 6, (1651-1659), 10.1007/s10620-019-05570-1)

Andres J. Yarur, Alexandra Bruss, Snehal Naik, Poonam Beniwal-Patel, Caroline Fox, Anjali Jain, Brandon Berens, Amir Patel, Ryan Ungaro, Bayda Bahur, Marla Dubinsky, Daniel J. Stein

Research output: Contribution to journal › Comment/debate

Abstract

The original version of the article unfortunately contained a couple of errors. In ‘Methods’ section, ‘Outcomes’ subsection, the sentence ‘Endoscopic remission was defined as an SESCD = 2 in patients with CD and an EMS = 2 in UC patients while off corticosteroids.’ should read ‘Endoscopic remission was defined as an SES-CD = 2 in patients with CD and an EMS = 1 in UC patients while off corticosteroids.’ In Figure 1, legend of light blue coloured bars ‘In Endoscopic Remission at Week 52’ should be replaced with ‘Not in Endoscopic Remission at Week 52’. Corrected version of Fig. 1 is given below.

Original language	English
Pages (from-to)	3674-3675
Number of pages	2
Journal	Digestive Diseases and Sciences
Volume	64
Issue number	12
DOIs	https://doi.org/10.1007/s10620-019-05876-0
State	Published - 1 Dec 2019

Access to Document

10.1007/s10620-019-05876-0

Fingerprint

Dive into the research topics of 'Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases (Digestive Diseases and Sciences, (2019), 64, 6, (1651-1659), 10.1007/s10620-019-05570-1)'. Together they form a unique fingerprint.

Cite this

Yarur, A. J., Bruss, A., Naik, S., Beniwal-Patel, P., Fox, C., Jain, A., Berens, B., Patel, A., Ungaro, R., Bahur, B., Dubinsky, M., & Stein, D. J. (2019). Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases (Digestive Diseases and Sciences, (2019), 64, 6, (1651-1659), 10.1007/s10620-019-05570-1). Digestive Diseases and Sciences, 64(12), 3674-3675. https://doi.org/10.1007/s10620-019-05876-0

@article{c225838b231044668b27e3dea57fb20e,

title = "Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases (Digestive Diseases and Sciences, (2019), 64, 6, (1651-1659), 10.1007/s10620-019-05570-1)",

abstract = "The original version of the article unfortunately contained a couple of errors. In {\textquoteleft}Methods{\textquoteright} section, {\textquoteleft}Outcomes{\textquoteright} subsection, the sentence {\textquoteleft}Endoscopic remission was defined as an SESCD = 2 in patients with CD and an EMS = 2 in UC patients while off corticosteroids.{\textquoteright} should read {\textquoteleft}Endoscopic remission was defined as an SES-CD = 2 in patients with CD and an EMS = 1 in UC patients while off corticosteroids.{\textquoteright} In Figure 1, legend of light blue coloured bars {\textquoteleft}In Endoscopic Remission at Week 52{\textquoteright} should be replaced with {\textquoteleft}Not in Endoscopic Remission at Week 52{\textquoteright}. Corrected version of Fig. 1 is given below.",

author = "Yarur, {Andres J.} and Alexandra Bruss and Snehal Naik and Poonam Beniwal-Patel and Caroline Fox and Anjali Jain and Brandon Berens and Amir Patel and Ryan Ungaro and Bayda Bahur and Marla Dubinsky and Stein, {Daniel J.}",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2019",

month = dec,

day = "1",

doi = "10.1007/s10620-019-05876-0",

language = "English",

volume = "64",

pages = "3674--3675",

journal = "Digestive Diseases and Sciences",

issn = "0163-2116",

number = "12",

}

Yarur, AJ, Bruss, A, Naik, S, Beniwal-Patel, P, Fox, C, Jain, A, Berens, B, Patel, A, Ungaro, R, Bahur, B, Dubinsky, M & Stein, DJ 2019, 'Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases (Digestive Diseases and Sciences, (2019), 64, 6, (1651-1659), 10.1007/s10620-019-05570-1)', Digestive Diseases and Sciences, vol. 64, no. 12, pp. 3674-3675. https://doi.org/10.1007/s10620-019-05876-0

Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases (Digestive Diseases and Sciences, (2019), 64, 6, (1651-1659), 10.1007/s10620-019-05570-1). / Yarur, Andres J.; Bruss, Alexandra; Naik, Snehal et al.
In: Digestive Diseases and Sciences, Vol. 64, No. 12, 01.12.2019, p. 3674-3675.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases (Digestive Diseases and Sciences, (2019), 64, 6, (1651-1659), 10.1007/s10620-019-05570-1)

AU - Yarur, Andres J.

AU - Bruss, Alexandra

AU - Naik, Snehal

AU - Beniwal-Patel, Poonam

AU - Fox, Caroline

AU - Jain, Anjali

AU - Berens, Brandon

AU - Patel, Amir

AU - Ungaro, Ryan

AU - Bahur, Bayda

AU - Dubinsky, Marla

AU - Stein, Daniel J.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The original version of the article unfortunately contained a couple of errors. In ‘Methods’ section, ‘Outcomes’ subsection, the sentence ‘Endoscopic remission was defined as an SESCD = 2 in patients with CD and an EMS = 2 in UC patients while off corticosteroids.’ should read ‘Endoscopic remission was defined as an SES-CD = 2 in patients with CD and an EMS = 1 in UC patients while off corticosteroids.’ In Figure 1, legend of light blue coloured bars ‘In Endoscopic Remission at Week 52’ should be replaced with ‘Not in Endoscopic Remission at Week 52’. Corrected version of Fig. 1 is given below.

AB - The original version of the article unfortunately contained a couple of errors. In ‘Methods’ section, ‘Outcomes’ subsection, the sentence ‘Endoscopic remission was defined as an SESCD = 2 in patients with CD and an EMS = 2 in UC patients while off corticosteroids.’ should read ‘Endoscopic remission was defined as an SES-CD = 2 in patients with CD and an EMS = 1 in UC patients while off corticosteroids.’ In Figure 1, legend of light blue coloured bars ‘In Endoscopic Remission at Week 52’ should be replaced with ‘Not in Endoscopic Remission at Week 52’. Corrected version of Fig. 1 is given below.

UR - http://www.scopus.com/inward/record.url?scp=85074053317&partnerID=8YFLogxK

U2 - 10.1007/s10620-019-05876-0

DO - 10.1007/s10620-019-05876-0

M3 - Comment/debate

C2 - 31642007

AN - SCOPUS:85074053317

SN - 0163-2116

VL - 64

SP - 3674

EP - 3675

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

IS - 12

ER -

Yarur AJ, Bruss A, Naik S, Beniwal-Patel P, Fox C, Jain A et al. Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases (Digestive Diseases and Sciences, (2019), 64, 6, (1651-1659), 10.1007/s10620-019-05570-1). Digestive Diseases and Sciences. 2019 Dec 1;64(12):3674-3675. doi: 10.1007/s10620-019-05876-0